Abstract: A separator for a rechargeable lithium battery, negative electrode-separator assembly for a rechargeable lithium battery, and rechargeable lithium battery are provided. The separator includes a ceramic layer including ceramic particles and a binder, and a functional layer on the ceramic layer including inorganic particles having a working potential (vs Li/Li+) of greater than or equal to about 1 V and a binder.

Abstract: A display device includes a light emitting area and a non-light emitting area, a light emitting element disposed in the light emitting area on a substrate and including a pixel electrode, a light emitting layer, and an upper electrode, the pixel electrode, light emitting layer, and upper electrode being sequentially disposed, a light blocking layer disposed on the light emitting element in the non-light emitting area, and a reflection control layer disposed on the light emitting element, covering the light blocking layer, and including a recess depressed concavely from an upper surface in the light emitting area.

Abstract: A display apparatus includes a first light-emitting element implementing a first emission area, a second light-emitting element implementing a second emission area, a low reflection layer on the first light-emitting element and the second light-emitting element, a first touch insulating layer including a first opening overlapping the second emission area, and a second touch insulating layer including a second opening overlapping the first opening, a light-blocking layer on the touch sensing layer and including a third opening corresponding to the first emission area and a fourth opening corresponding to the second emission area, and a reflection-adjusting layer wherein a refractive index of the reflection-adjusting layer is higher than a refractive index of the second touch insulating layer.

Abstract: Certain embodiments are directed to methods and composition for detecting the level of GFR?1 in cancers and treating same.

Abstract: The invention relates to the treatment and diagnosis of organ dysfunction caused by ischemia reperfusion injury. In particular, the invention relates to sphinganine-1-phosphate, a sphingolipid metabolite, and its use in the diagnosing, preventing, and/or treating ischemia reperfusion-associated disorders, including, without limitation, disorders of the kidney, liver, lung, brain, and heart.